Pediatric Therapy Articles & Analysis
4 news found
” Interim Results From an Ongoing Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) The oral presentation includes efficacy and safety data (cut-off March 9, 2022) at three to 24 months of follow-up after RP-L201 infusion for all patients and overall survival data for ...
In 2019, NeuroSigma’s Monarch eTNS System became the first-ever non-pharmaceutical treatment to receive FDA clearance as a treatment for pediatric ADHD. To deliver therapy with the Monarch, patients place an adhesive electric patch on their forehead. ...
New treatments are needed to target this risk factor whilst working synergistically with current therapies,” said Dr. Franz Schaefer, Professor of Pediatrics and Chief of the Pediatric Nephrology Division at Heidelberg University Hospital. ...
ByBayer AG
Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, ...